Sharpless Sworn in as Director of NCI
On October 17, 2017, Norman "Ned" Sharpless was
sworn in as the 15th Director of the National Cancer Institute (NCI). Prior to his appointment, Sharpless was director of the UNC Lineberger Comprehensive Cancer Center, served on the board of directors of the Associate of American Cancer Institutes (AACI), and
was a member of the American Association for Cancer Research (AACR) Science Policy and Government Affairs Committee.
In a statement released by AACI, Stan Gerson, MD, AACI President and Director of the Case CCC, said, "Ned is an accomplished physician-scientist and a strong advocate for both basic and translational cancer research. As a fellow leader of an NCI-designated cancer center, I congratulate Ned and look forward to his guidance at the national level."
Sharpless replaced Douglas Lowy, MD, who served as NCI Acting Director since spring of 2015 when Harold Varmus, MD stepped down.
|
2nd Annual Cancer Disparities Symposium
The Case Comprehensive Cancer Center Office of Cancer Disparities Research will host the 2nd Annual Cancer Disparities Symposium on
Friday, March 23, 2018. Details and registration information will be circulated soon!
|
20th Annual Midwest DNA Repair Symposium
The Midwest DNA Repair Symposium is scheduled for
May 5-6, 2018 on the campus of Case Western Reserve University.
The Planning Committee is pleased to welcome Keynote Speakers
Stephen Kowalczykowski, Distinguished Professor of Microbiology and Molecular Genetics, and of Molecular and Cellular Biology, University of California, Davis, and
Lee Zou, Professor of Pathology, Harvard Medical School; Associate Scientific Director, Massachusetts General Hospital Cancer Center; James & Patricia Poitras Endowed Chair.
More information will be posted soon.
|
Cancer Stem Cells 2018
Cancer Stem Cell Conference (CSC 2018) is scheduled for August 12-15, 2018. This exciting conference, hosted by the Case Comprehensive Cancer Center and National Center for Regenerative Medicine, is designed to bring together individuals working in the field of cancer stem cell research. CSC 2018 will feature renowned keynote speakers and leaders in the field. This conference is guaranteed to have cutting edge research from a variety of niches within the field. Watch the newsletter for more information.
|
WKSU - Oct 30, 2017
The Cleveland Clinic for years has asked to use samples from patients to study diseases,
cataloging more than 90,000 specimens. The program will get a serious upgrade with the construction of the new Biobank facility on the Clinic's campus.
The planned facility will increase capacity, giving researchers more samples to compare diseased tissue and healthy tissue side-by-side.
"To (help) predict clinical course and really refine our treatment plans to each patient based on the specific attributes even beyond the initial diagnosis and classification," said Dr. Jennifer Ko, Medical Director for the Clinic's Central Biorepository and co-Director for the Case CCC Tissue Shared Resource.
|
News5 Cleveland- Oct 27, 2017
Melanoma can be a terrifying and even deadly disease. Up until now, there has also been a lot of mystery when it comes to just how long you can wait between getting diagnosed and treatment. But a groundbreaking new study is answering that question and changing how the skin cancer is treated...
Dr Brian Gastman, Case Comprehensive Cancer Center, surgical director for melanoma at Cleveland Clinic, says acting fast made all the difference for Liz. "
The tumor could have been easily larger and she could have been a higher stage as a result," he said. "The fact that we were able to get to her earlier means that her stage was lower."
Turns out, tackling melanoma at an early stage is key. Researchers at Cleveland Clinic studied more than 150,000 patients through the National Cancer Database. They found waiting more than 90 days for surgery decreased survival rates at all stages, while the earlier the melanoma was treated in Stage I - within the first 30 days - the better.
|
Reuters - Oct 26, 2017
Gastrointestinal (GI) disorders such as Crohn's disease and Barrett's esophagus get a bigger slice of U.S. public research funding than other GI conditions that affect many more Americans, researchers say...As NIH funding remains restricted, researchers and GI advocacy groups should look at all possible sources of funding, including industry, foundations and other federal sources such as the Department of Defense, said Dr. Gregory Cooper,
Program Director of Gastroenterology at UH Cleveland Medical Center, and
co-Leader of the Cancer Prevention, Control and Population Research Program, Case Comprehensive Cancer Center, who wasn't involved in the study. "Funding for biomedical research is chronically lower than it ought to be," he told Reuters Health by email. "Patient advocacy groups are important in lobbying for additional funding, and disease-specific foundations can help support research."
|
New technology makes mammograms more comfortable, less painful
News5 Cleveland- Oct 18, 2017
We all know how important mammograms are in the fight against breast cancer, but they are not always the most comfortable experience.
Engineers have been working on a new device for years aimed at changing that and making the process more comfortable. University Hospitals is part of the study and the new technology could become standard in a matter of weeks.
Several years ago, UH became the first site in Northeast Ohio to offer 3D mammograms. "
If I compare these two images, I can actually scroll through the breast kind of like looking at different pages of a book, as opposed to just looking at the cover of the book," explained Dr. Donna Plecha, Case Comprehensive Cancer Center, co-director of UH MacDonald Women's Hospital Breast Centers.
|
Case GI SPORE
Deadline: Nov 10, 2017
The Case GI SPORE has released the following requests for project proposals:
DRP proposals will be considered for any GI malignancy, priority consideration will be given to proposals focused on non-colorectal GI malignancies. In addition, we plan to award at least 1 DRP per cycle to a non colorectal focused proposal. Developmental Research Projects in the area of Pancreatic Cancer are encouraged.
All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or human materials.
|
Cancer Moonshot
The National Cancer Institute is pleased to announce the release of
17 new Cancer Moonshot funding opportunities
. Efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible.
|
Rally Foundation for Childhood Cancer Research Collaborative Pediatric Cancer Research Awards Program
LOI Deadline: Dec 1, 2017
Rally Foundation for Childhood Cancer Research is accepting applications for the following funding opportunities:
Fellowship Grants: Grants are for one or two years support. Each funded grant will be awarded up to $50,000 per year.
Young Investigator and Independent Investigator Research Grants: Grants are for one or two years
support. Each funded grant will be awarded up to $50,000 per year.
Consortium Grants: Grants are for one or two years support. Each funded grant will be awarded up to $100,000 per year.
|
Pilot Awards to Understand and/or Reduce Health Disparities
Deadline: Dec 15, 2017
The Center for Reducing Health Disparities invites applications for pilot awards to understand and/or reduce health disparities. These awards aim to develop investigators with a high capacity to engage in partnerships with communities to conduct high-quality health disparities research. Investigations of interest include the development, pilot testing, and/or dissemination of community-based studies to understand and/or eliminate health disparities.
Awardees will receive project assistance from the Investigator Development Core of the Center for Reducing Health Disparities and its Community-Based Research Network (CBRN). Awardees will be expected to make presentations at our health disparities seminars and CBRN meetings and will be invited to interact with visiting speakers, contribute to a health disparities course, and participate in community dissemination forums.
Final decisions on all awards will be made by the National Institutes of Health.
|
Department of Defense (DoD) Kidney Cancer Research Program
LOI Deadline: Dec 20, 2017; Application Deadline: Jan 4, 2018
The FY17 Defense Appropriations Act provides $10M to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). Applications are being accepted for the following opportunities:
Consortium Development Award: is a clinical trial infrastructure mechanism that provides support to create a Coordinating Center and to establish the necessary collaborations at potential Clinical Trial Sites for the development of a multi-institutional kidney clinical effort relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The goal of the Consortium Development Award is the establishment of the consortium infrastructure for future multi-institutional clinical trials.
Idea Development Award: intended to support innovative ideas and highimpact approaches based on scientifically sound evidence to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Personnel on the proposed team should have a strong background in kidney cancer research.
Concept Award: supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation relevant to active duty Service members, Veterans, other military beneficiaries, and the American public.
Translational Research Partnership Award: supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty level (or equivalent) investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged.
|
AACR-Thomas J. Bardos Science Education Awards for Undergraduate Students
Deadline: TBD
The American Association for Cancer Research (AACR) is pleased to offer Science Education Awards for Undergraduate Students for participation in two consecutive AACR Annual Meetings. Available to full-time, third-year undergraduate students majoring in science, the purpose of these awards is to inspire promising science students to enter the field of cancer research.
|
NIH BULLETIN- Notices and Funding Opportunities
|
|
|
FOLLOW US
|
EVENTS
|
|
Wed, Nov 1
Immunology and Rheumatologic and Immunologic Disease Invited Seminar Series
Breck A. Duerkop, PhD
University of Colorado School of Medicine
"The Impact of Intestinal Bacteriophages on Host-Microbe Interactions"
12p NC1-202
|
|
Thurs, Nov 2
Developmental Therapeutics Journal Club
9a R4-013
Tumor Immunology and Immunotherapy
4p WRB 3-136
|
|
Fri, Nov 3
Hem/Onc Div Research Conf
Priyanka Bhateja, MD
Fellow, Div. of Hem/Onc, CWRU/UHCMC
"Linda K. Arena Endowed Scholarship Award: Genomic Biomarkers in Lung cancer: An Update"
8a Wearn 137
TCI Grand Rounds
Nancy Cochran, MD
Dartmouth University
"It's Not About Winning: Engaging Constructively in Conflict"
8a CA5-120
Genomic Medicine Institute
Dennis Lal, PhD
Broad Institute of MIT and Harvard Stanley Center for Psychiatric Research
"Understanding neurodevelopmental disorders using genetic, biological and clinical data sets"
10:30a NE1-205
Cancer Center Seminar Series
Agata Exner, PhD
Professor, Radiology & Biomedical Engineering, CWRU
"Echogenic Nanobubbles: New opportunities for ultrasound molecular imaging beyond tumor vasculature"
12p WRB 1-413
|
|
Tues, Nov 7
THOR Seminar
Paul Beming
Formulatrix
"Automation to miniaturize genomics applications
1p NE1-205
Cancer Center Research in Progress Seminar
3p WRB 3-136 |
|
Wed, Nov 8
Breast Cancer Update: From Screening Through Treatment to Survivorship
8a-3:15p Embassy Suites, Independence
Immunology Students/Fellows Research In Progress Series
Shinji Okano, MD, PhD
Research Fellow, General Surgery
12p NC1-202
|
|
Thurs, Nov 9
Developmental Therapeutics Journal Club
9a R4-013
Biochemistry
Guest Seminar Series
Jerry Pelletier, PhD
Professor, Biochemistry,McGill University
"Targeting eIF4F-dependencies in disease"
12p Wood W428
|
|
Fri, Nov 10
TCI Grand Rounds
Sagar Patel, MD
Cleveland Clinic
"The challenges of non-relapse mortality in allogeneic hematopoietic CCF cell transplantation"
8a CA5-120
Cellular and Molecular Medicine
Navdeep S. Chandel, PhD
Professor, Medicine and Cell Biology, Northwestern University
"Mitochondria as signaling organelles"
10a NC1-202
Cancer Center Seminar Series
Alexandru Almasan, PhD
Co-Leader, Molecular Oncology Program, Case Comprehensive Cancer Center
Professor, Cancer Biology, Radiation Oncology, CWRU/Cleveland Clinic
"Exploiting vulnerabilities in the DNA damage repair of prostate cancer cells"
12p WRB 1-413 |
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
Best of Radiation Oncology 2017
Nov 11, 2017
Crowne Plaza, Independence
Global Adolescent & Young Adult Cancer Congress
Dec 5-7, 2017
Atlanta, GA
Deadline to submit abstracts: Sep 1, 2017
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline: Open
Deadline: Open
Deadline: Open
|
|
 |
|
